2 August 2023 - Approval for Tecvayli, a subcutaneously administered therapy, is based on results from the Phase 1/2 MajesTEC-1 study that showed deep and durable responses in triple class exposed patients with relapsed or refractory multiple myeloma.

Janssen announced today that Health Canada has issued a Notice of Compliance with conditions for Tecvayli (teclistamab injection) for the treatment of adult patients with relapsed or refractory multiple myeloma who have received at least three prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent and an anti-CD38 monoclonal antibody, and who have demonstrated disease progression on the last therapy.

Read Janssen press release